Evidence Hub

MP79-15 ERECTILE FUNCTION RECOVERY AMONG YOUNG MEN WITH ERECTILE DYSFUNCTION ON OaD TADALAFIL 5 MG: FINDINGS FROM A REAL-LIFE STUDY

E. Pozzi, F. Belladelli, G. Fallara, S. Cilio, C. Corsini, A. Bertini, M. Raffo, Fausto Negri et al.

Journal of Urology, 2023

Abstract

prospectively collected at a single Sexual Medicine clinic in 2005-2022 were analysed. Overall, 342(8.3%) patients complained of PE and were treated either with dapoxetine 30-60mg prn or paroxetine 20mg OaD according to patients' profile and preference. All completed the Premature Ejaculation Diagnostic Tool (PEDT) and the IIEF before and over the treatment course. Patients were re-assessed at 3 months from treatment start and thereafter every 6 months or as needed. KaplanMeier estimated treatment drop-out rates over time. Cox regression analysis assessed predictors of treatment discontinuation. RESULTS: Median (IQR) age was 47(36, 61) years. Median baseline PEDT score was 15 (10,17.5). Of all, 151(44%) and 191(56%) patients were treated with dapoxetine and paroxetine respectively. Patients receiving dapoxetine were younger (40(30,48) vs. 56(41,67); p<0.0001) and depicted worse baseline PEDT (16(14,18) vs. 8(3,14); p<0.0001) as compared with those receiving paroxetine. Overall, 329(96%) discontinued the drugs at some point throughout the treatment course, showing only a slight mean improvement of PEDT from baseline of -0.4(95%CI:-0.8,1.7) and -0.8(95%CI:-0.7,1.3) with dapoxetine and paroxetine, respectively. At Kaplan-Meier (Figure 1) the two groups did not differ in terms of treatment dropout over time (p[0.3), with estimated discontinuation rates of 27%(15,45) and 55%(37,75) at 12 and 24 months for dapoxetine and 13%(7,24) and 47%(32,65) for paroxetine. Younger patients…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free